| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:WYJ-2
CAS:3029403-05-9
Package:10mg;50mg
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Email: |
info@biorbyt.com |
| Products Intro: |
Product Name:WYJ-2
CAS:3029403-05-9
|
|
| Product Name: | WYJ-2 | | Synonyms: | WYJ-2;1,2,4-Oxadiazole, 3-(6-fluoro-2H-1-benzopyran-3-yl)-5-(2-fluoro-5-nitrophenyl)- | | CAS: | 3029403-05-9 | | MF: | C17H9F2N3O4 | | MW: | 357.27 | | EINECS: | | | Product Categories: | | | Mol File: | 3029403-05-9.mol |  |
| | WYJ-2 Chemical Properties |
| Boiling point | 540.230±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.504±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | -2.478±0.10(predicted) |
| | WYJ-2 Usage And Synthesis |
| Uses | WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC)[1]. | | in vivo | WYJ-2 (5 mg/kg, i.p. every teo days for 30 days) inhibits tumor growth without significant toxicity in A549 xenograft BALB/c mice[1].
WYJ-2 (10 mg/kg, i.p.) exhibits a pharmacokinetic profil with half-time of T1/2 of 3.67 h and a clearance Cmax of 497 ± 49 ng/mL[1]. | Animal Model: | A549 xenograft BALB/c mice[1] | | Dosage: | 5 mg/kg | | Administration: | i.p. every two days for 30 days | | Result: | Inhibited tumor growth with a TGI of 72.22% without significant loss of body weight. |
| | IC 50 | TLR2 | | References | [1] Wang Y, et al., Design and Synthesis of 3-(2H-Chromen-3-yl)-5-aryl-1,2,4-oxadiazole Derivatives as Novel Toll-like Receptor 2/1 Agonists That Inhibit Lung Cancer In Vitro and In Vivo. J Med Chem. 2024 Mar 18. DOI:10.1021/acs.jmedchem.3c01984 |
| | WYJ-2 Preparation Products And Raw materials |
|